Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Gracell to Start China Trial of Donor-derived CAR-T Therapy for B-ALL

publication date: Jan 13, 2021

Gracell Biotech, a Suzhou company developing novel CAR-T therapies, was approved to start a China Phase I/II clinical trial of its allogeneic donor-derived CD19 CAR-T cell therapy. GC007g will be tested in patients with B-cell acute lymphoblastic leukemia (B-ALL). It will be administered to B-ALL patients who relapsed after receiving an allogeneic transplant and are not eligible for autologous CAR-T therapy because of compromised T-cells. Gracell said the seamless, potentially pivotal Phase I/II clinical trial of GC007g will accelerate clinical development of GC007g. More details....

Stock Symbol: (NSDQ: GRCL)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.